Pantherna Therapeutics announces grant of Key European Patent for its advanced mRNA expression technology.
Hennigsdorf, December 27, 2023

Pantherna Therapeutics, a privately held biotechnology company developing first-in-class therapeutics based on its proprietary mRNA-LNP technologies, today announced that European patent EP3833786B has been issued by the European Patent Office (EPO), securing an innovative, universally applicable mRNA expression cassette for enhanced translation of proteins aiming at restoring cellular function in the context of mRNA therapies.
“The decision of the EPO marks an important step for Pantherna in building a comprehensive patent portfolio to protect its mRNA-based platform technology and drug candidates”, said Dr. Klaus Giese, CEO of Pantherna Therapeutics.

Contact for additional information:  
Dr. Ansgar Santel, Head of Translational Research and Alliance Management  

T: +49(0)3302-202 240-0  
E-Mail: a.santel@pantherna-therapeutics.com